Skip to content
HowShorted

Adamas Pharmaceuticals Inc short interest in 2020

In 2020, Adamas Pharmaceuticals Inc's disclosed short interest ran from 8.24% of shares outstanding on 15 Jan 2020 to 4.38% on 31 Dec 2020, a change of -3.86 percentage points. The year's high was 8.24% on 15 Jan 2020 and its low 2.54% on 15 Jul 2020, averaging 4.14% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.91 days on 30 Nov 2020. Full history: Adamas Pharmaceuticals Inc.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021

Aggregate net short position time series for Adamas Pharmaceuticals Inc in 2020

2020 in figures

Start of year
8.24% (15 Jan 2020)
End of year
4.38% (31 Dec 2020)
Change
-3.86 pp
High
8.24% (15 Jan 2020)
Low
2.54% (15 Jul 2020)
Average
4.14%
Highest days to cover
9.91 (30 Nov 2020)
SEC filings marked
9

Every report in 2020

Adamas Pharmaceuticals Inc short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 20208.24%2.46results (8-K)
31 Jan 20206.75%6.84
14 Feb 20205.06%7.07
28 Feb 20204.46%3.0210-K filed, results (8-K)
13 Mar 20204.73%2.71
31 Mar 20204.28%4.36
15 Apr 20203.82%3.44
30 Apr 20203.62%4.48
15 May 20204.16%3.0610-Q filed, results (8-K)
29 May 20203.71%3.15
15 Jun 20204.52%1.87
30 Jun 20203.31%1.54
15 Jul 20202.54%3.51
31 Jul 20202.77%3.76
14 Aug 20203.68%1.0010-Q filed, results (8-K)
31 Aug 20203.02%2.04
15 Sep 20202.78%3.69
30 Sep 20202.61%2.71
15 Oct 20202.65%4.92
30 Oct 20204.20%7.40
13 Nov 20204.15%6.4510-Q filed, results (8-K)
30 Nov 20204.07%9.91
15 Dec 20205.73%7.64
31 Dec 20204.38%8.14

See also: Adamas Pharmaceuticals Inc's full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.